Tectonic Therapeutics details TX45 Phase 2 trial design for Group 2 PH-HFpEF

Tectonic Therapeutic, Inc.

Phase 2 randomized, placebo-controlled, double-blind trial to start H2 2024 globally (US, Europe, Eastern Europe, Australia).
Trial enriches for patients with PVR >3 on right heart catheterization; ~180 subjects expected.
Subjects randomized 1:1:1 to two TX45 doses or placebo; 24-week treatment plus 8-week follow-up.
Goal: evaluate efficacy in combined pre- and post-capillary PH and whole Group 2 PH-HFpEF population.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.